These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22933817)

  • 21. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors.
    Seeman P
    Synapse; 2015 Apr; 69(4):183-9. PubMed ID: 25645960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease.
    Staubo SC; Fuskevåg OM; Toft M; Lie IH; Alvik KMJ; Jostad P; Tingvoll SH; Lilleng H; Rosqvist K; Størset E; Odin P; Dietrichs E; Dietrichs ES
    Eur J Neurol; 2024 Feb; 31(2):e16144. PubMed ID: 37955562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine agonist withdrawal syndrome (DAWS) in a patient with a microprolactinoma.
    Demartini B; Ricciardi L; Ward A; Edwards MJ
    J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):471. PubMed ID: 24078717
    [No Abstract]   [Full Text] [Related]  

  • 24. Screening for impulse control disorders in Parkinson's disease and dopamine agonist use: a study of pharmacokinetic and psychological risk factors.
    Contin M; Lopane G; Marini L; Mohamed S; Sambati L; De Massis P; Guarino M; Sermi S; Persichella C; Cortelli P; Calandra-Buonaura G
    Neurol Sci; 2023 Feb; 44(2):565-572. PubMed ID: 36350455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impulsive and compulsive behaviors in Parkinson Study Group (PSG) centers performing deep brain stimulation surgery.
    Hack N; Akbar U; Thompson-Avila A; Fayad SM; Hastings EM; Moro E; Nestor K; Ward H; York M; Okun MS
    J Parkinsons Dis; 2014; 4(4):591-8. PubMed ID: 25035311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching from pergolide to pramipexole in patients with Parkinson's disease.
    Hanna PA; Ratkos L; Ondo WG; Jankovic J
    J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists.
    Rizos A; Sauerbier A; Antonini A; Weintraub D; Martinez-Martin P; Kessel B; Henriksen T; Falup-Pecurariu C; Silverdale M; Durner G; Røkenes Karlsen K; Grilo M; Odin P; Chaudhuri KR;
    Eur J Neurol; 2016 Aug; 23(8):1255-61. PubMed ID: 27170229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: A cross-sectional multicenter study.
    Vela L; Martínez Castrillo JC; García Ruiz P; Gasca-Salas C; Macías Macías Y; Pérez Fernández E; Ybot I; Lopez Valdés E; Kurtis MM; Posada Rodriguez IJ; Mata M; Ruiz Huete C; Eimil M; Borrue C; Del Val J; López-Manzanares L; Rojo Sebastian A; Marasescu R
    J Neurol Sci; 2016 Sep; 368():150-4. PubMed ID: 27538621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine Agonists and Impulse Control Disorders: A Complex Association.
    Grall-Bronnec M; Victorri-Vigneau C; Donnio Y; Leboucher J; Rousselet M; Thiabaud E; Zreika N; Derkinderen P; Challet-Bouju G
    Drug Saf; 2018 Jan; 41(1):19-75. PubMed ID: 28861870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
    Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
    Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease.
    Smith KM; Xie SX; Weintraub D
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):864-70. PubMed ID: 26534930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Impulse control disorders in Parkinson's disease: A cohort of 35 patients].
    Carrière N; Kreisler A; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2012 Feb; 168(2):143-51. PubMed ID: 22129474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia.
    Holman AJ
    J Gambl Stud; 2009 Sep; 25(3):425-31. PubMed ID: 19241148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proficient motor impulse control in Parkinson disease patients with impulsive and compulsive behaviors.
    Claassen DO; van den Wildenberg WP; Harrison MB; van Wouwe NC; Kanoff K; Neimat JS; Wylie SA
    Pharmacol Biochem Behav; 2015 Feb; 129():19-25. PubMed ID: 25459105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety considerations when using non-ergot dopamine agonists to treat Parkinson's disease.
    Stocchi F; Fossati B; Torti M
    Expert Opin Drug Saf; 2020 Sep; 19(9):1155-1172. PubMed ID: 32869676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
    Haaxma CA; Horstink MW; Zijlmans JC; Lemmens WA; Bloem BR; Borm GF
    J Parkinsons Dis; 2015; 5(4):847-53. PubMed ID: 26444087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Impulse control disorders associated with dopaminergic agonists in Parkinson's disease. Case report].
    Gamboa Arango A; Bernal Bernal MT; Duaso Magaña E
    Rev Esp Geriatr Gerontol; 2016; 51(5):304-5. PubMed ID: 27016028
    [No Abstract]   [Full Text] [Related]  

  • 38. Long term follow-up of Parkinson's disease patients with impulse control disorders.
    Sohtaoğlu M; Demiray DY; Kenangil G; Ozekmekçi S; Erginöz E
    Parkinsonism Relat Disord; 2010 Jun; 16(5):334-7. PubMed ID: 20223696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Multicenter Comparative Study of Impulse Control Disorder in Latin American Patients With Parkinson Disease.
    Ramírez Gómez CC; Serrano Dueñas M; Bernal O; Araoz N; Sáenz Farret M; Aldinio V; Montilla V; Micheli F
    Clin Neuropharmacol; 2017; 40(2):51-55. PubMed ID: 28288482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopaminergic agonists in Parkinson's disease.
    Alonso Cánovas A; Luquin Piudo R; García Ruiz-Espiga P; Burguera JA; Campos Arillo V; Castro A; Linazasoro G; López Del Val J; Vela L; Martínez Castrillo JC
    Neurologia; 2014 May; 29(4):230-41. PubMed ID: 21724302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.